Publications by authors named "Louise Martin-Carpenter"
Article Synopsis
- Long-term antiretroviral therapy (ART) for HIV can lead to issues like dyslipidemia and increased cardiovascular risks, making it essential to choose antiretroviral drugs that positively influence lipid levels.
- Dolutegravir, a newer HIV integrase inhibitor, was found to have a neutral effect on lipid levels compared to other treatments like efavirenz and darunavir, showing smaller increases in total cholesterol and triglycerides after 48 weeks.
- Overall, dolutegravir is associated with favorable lipid outcomes and lower cardiovascular risk, making it a preferred choice in combination ART regimens.
The majority of HIV-1 integrase amino acid sites are highly conserved, suggesting that most are necessary to carry out the critical structural and functional roles of integrase. We analyzed the 34 most variable sites in integrase (>10% variability) and showed that prevalent polymorphic amino acids at these positions did not affect susceptibility to the integrase inhibitor dolutegravir (S/GSK1349572), as demonstrated both in vitro (in site-directed mutagenesis studies) and in vivo (in a phase IIa study of dolutegravir monotherapy in HIV-infected individuals). Ongoing clinical trials will provide additional data on the virologic activity of dolutegravir across subject viruses with and without prevalent polymorphic substitutions.
View Article and Find Full Text PDF